2023年国际肺癌研究协会（IASLC）世界肺癌大会（WCLC）将于2023年9月9日至12日将在新加坡盛大举行。WCLC是肺癌领域的年度盛典，每年都会有众多重磅研究结果公布并由此更新临床实践。为此，“医学界”特梳理了今年WCLC大会上小细胞肺癌（SCLC）相关重磅研究进展，在WCLC开幕之前，一起先睹为快！

广泛期SCLC的免疫治疗进展

OA01. Advancing Immunotherapy in ES-SCLC

在今年WCLC的口头报道上，免疫治疗的组合搭档可谓百花齐放，除了与化疗联合，还与抗血管生成药物进行组合搭配。此外，还有新靶点药物初露锋芒。

①OA01.03 一项随机、双盲、III期试验：Benmelstobart+安罗替尼+化疗作为广泛期SCLC的一线治疗方案

Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial

讲者：程颖教授，吉林省肿瘤医院

②OA01.04 一项伞式扩展研究结果：IMpower133研究中接受阿替利珠单抗治疗的广泛期SCLC患者5年生存率

Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

讲者：S.V. Liu| Lombardi Comprehensive Cancer Center, Georgetown University, Washington/DC/USA

③OA01.05 一项I期聚焦于SCLC的剂量递增试验：IgG样T细胞重定向DLL3/CD3双抗BI 764532用于DLL3阳性患者

Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC

讲者：M. Wermke| TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden/DE

④OA01.06 III期RATIONALE-312研究：一线化疗±替雷利珠单抗用于广泛期SCLC

First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

讲者：程颖教授，吉林省肿瘤医院

下一代明星药物席卷而来：抗体偶联药物

OA05. Antibody Drug Conjugates: The Next Tsunami

抗体偶联药物（ADC）在乳腺癌等实体瘤中逐步突破“壁垒”，获批多项适应症。作为较为难治的一种肺癌亚型，“精准导弹”能否攻克SCLC难题？HER3、TROP2等八点药物即将公布数据，值得期待。

①OA05.03 HERTHENA-Lung01研究：EGFR突变NSCLC患者接受EGFR-TKI和铂类化疗后使用HER3-DXd Patritumab Deruxtecan

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

讲者：H.A. Yu| Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/NY/USA

②OA05.04 EVOKE-02研究的初步结果：戈沙妥珠单抗+帕博利珠单抗用于一线治疗NSCLC

Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

讲者：B.C. Cho| Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR

③OA05.05 一项1/2期亚组研究分析：Ifinatamab Deruxtecan (DS-7300) 用于难治性SCLC

Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study

讲者：M. Johnson| Sarah Cannon Research Institute, Nashville/TN/USA

④OA05.06 1b期TROPION-Lung04研究的初步结果：Datopotamab Deruxtecan+度伐利尤单抗±卡铂治疗晚期/转移性NSCLC

Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04

讲者：K.P. Papadopoulos| START San Antonio, San Antonio/TX/USA

完善小细胞肺癌相关研究，重新定义标准

MA18. Refining Practice and Redefining Standards in SCLC

①MA18.03 一项3期试验的初步安全性和疗效结果：低分割 vs 传统分割同步放化疗治疗局限期SCLC

Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC

讲者：毕楠教授，中国医学科学院肿瘤医院

②MA18.04 局限性SCLC的预后因素：CALGB 30610/RTOG 0538的二次分析

Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC) : Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538

讲者：M.K. Farri| Atrium Health Wake Forest Baptist Medical Center, Winston Salem/NC/USA

③MA18.05 预防性全脑照射用于局限期SCLC其脑转移风险和生存获益的生物标志物

Biomarkers for Brain Metastases Risk and Survival Benefit of Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer

讲者：L. Li| Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan/CN

④MA18.06 在CALGB 140503研究后，重新评估早期SCLC的亚肺叶切除术与肺叶切除术

Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503

讲者：C.S. Haridas| Massachusetts General Hospital, Boston/MA/USA

⑤MA18.08A 卡铂+依托泊苷+尼达尼布治疗不可切除SCLC伴特发性肺纤维化的2期研究

Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis

讲者：Y. Agemi| Yokohama Municipal Citizen’s Hospital, Yokohama-city/JP

⑥MA18.09 GOIRC-01-2019 CeLEBrATE试验：卡铂、依托泊苷、贝伐珠单抗和阿替利珠单抗在广泛期SCLC患者中的应用

Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial

讲者：G. Lamberti| Università di Bologna, Bologna/IT

⑦MA18.10 一项2期多队列研究：LSD1抑制剂CC-90011联合纳武利尤单抗治疗晚期肺癌

Phase 2 Multicohort Study of CC-90011, a LSD1 Inhibitor, in Combination with Nivolumab in Patients with Advanced Lung Cancer

讲者：E. Carcereny| Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona. Badalona-Applied Research Group in Oncology (B-ARGO), Badalona (Barcelona)/ES

⑧MA18.11 一项Ib/II期研究的最新结果：Senaparib联合低剂量替莫唑胺治疗复发广泛期SCLC患者

A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients

讲者：M.H. Hong| Yonsei University College of Medicine, Seoul/KR

责任编辑：Sheep